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Recently, steroid hormones quantification in blood showed a promising ability to detect 19 
testosterone doping and interesting complementarities with the urinary module of the Athlete 20 
Biological Passport (ABP). In this work, an ultra-high pressure liquid chromatography–high-21 
resolution mass spectrometry (UHPLC-HRMS) method was developed for the quantification of 22 
eleven endogenous steroids in serum. The performance of the full scan and targeted SIM 23 
acquisition modes was evaluated and compared to the performance of tandem mass 24 
spectrometry (MS/MS). Passing-Bablok regressions and Bland-Altman plots were assessed for 25 
each analyte of interest, and concentration values measured by HRMS showed high correlation 26 
with the ones obtained by MS/MS for all target hormones, with low absolute differences in the 27 
majority of cases. A slight decrease in terms of sensitivity was observed with HRMS in both 28 
acquisition modes, but performing an analysis of variance multiblock orthogonal partial least 29 
squares (AMOPLS) on the dataset obtained with all three methods revealed that only 0.8% of 30 
the total variance was related to instrumentation and acquisition methods. Moreover, the 31 
evaluation of the testosterone administration effect over time highlighted testosterone itself 32 
and dihydrotestosterone as the most promising biomarkers of exogenous testosterone 33 
administration. This conclusion suggests that HRMS could provide suitable performance for 34 
blood steroid analysis in the anti-doping field. 35 
 36 
 37 
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1. Introduction 39 
The detection of testosterone (T) abuse in sport is currently achieved through the steroidal 40 
module of the Athlete Biological Passport (ABP). The so-called “steroid profile” was 41 
implemented in 2014, and it is obtained from urinary concentrations of six endogenous anabolic 42 
androgenic steroids (EAAS) measured by gas chromatography-(tandem) mass spectrometry (GC-43 
MS(/MS)). It consists of longitudinal monitoring, with individual reference intervals calculated 44 
by a Bayesian adaptive model, of five ratios known to be potentially altered following the 45 
administration of synthetic forms of EAAS: androsterone/testosterone (A/T), 46 
androsterone/etiocholanolone (A/Etio), 5α-androstane-3α,17β-diol/5β-androstane-3α,17β-diol 47 
(5αAdiol/5βAdiol), 5α-androstane-3α,17β-diol/Epitestosterone (5αAdiol/E) and the most 48 
important, testosterone/epitestosterone (T/E) [1]. Although this new approach clearly improved 49 
detection capabilities in comparison with the previous population threshold criterion of T/E > 4, 50 
it still suffers from major drawbacks. These include the large presence in the urine matrix of 51 
both endogenous (e.g., metabolism, ethnicity) and exogenous (e.g., ethanol, bacterial 52 
contamination) confounding factors, which can influence either the quantification of the urinary 53 
steroid profile or its interpretation [2], and the difficulty of detecting doping in individuals with a 54 
genetic polymorphism for UGT2B17 enzyme activity [3-6] and/or in athletes who have been 55 
administered T gel and patch formulations [7].  56 
In the last few years, several studies have been conducted with the aim of improving steroid 57 
abuse detection capabilities. At first, major efforts were focused on the identification, by means 58 
of GC-MS(/MS) platforms, of new urinary biomarkers of EAAS abuse to be added to the panel of 59 
ratios included in the steroid profile [8-11]. Then, research broadened and oriented to UHPLC-60 
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MS/MS methods as well, as this type of technique is faster, more sensitive and capable of 61 
detecting phase II metabolites of steroid hormones in their intact form [12-14], unlike GC-MS 62 
analysis which always requires a derivatization step, eventually preceded by a hydrolysis step. 63 
More recently, high-resolution mass spectrometry (HRMS) has also been used to provide 64 
innovation in the context of steroid analysis. Indeed, holistic approaches such as metabolomics 65 
(defined as steroidomics [15]), allowed the untargeted evaluation of a large number of 66 
compounds, thus also representing a promising strategy for the discovery of new biomarkers 67 
and metabolites for anti-doping purposes [16, 17]. Nevertheless, the use of HRMS platforms by 68 
anti-doping laboratories for screening analyses is constantly increasing [18-21], even if their use 69 
for quantification purposes is still not widespread.  70 
In the anti-doping field, both endogenous and exogenous steroids have been traditionally 71 
analyzed in urine, but a first attempt of endogenous steroid analysis in blood was recently 72 
conducted [22]. The blood matrix is clearly more difficult to manipulate/contaminate than 73 
urine, and quantitative analysis of target compounds in blood represents a real snapshot of 74 
athlete physiological status, a key aspect for possibly better discriminating doping from 75 
pathologies. In addition, the study of steroid metabolism in blood could also be particularly 76 
relevant to explain diseases associated with a possible malfunction in steroidogenesis, in 77 
particular steroid metabolism enzymes (e.g. congenital adrenal hyperplasia, CAH) as well as in 78 
environmental sciences to better understand the mode of action of endocrine disrupting 79 
chemicals. On the other hand, the blood matrix also raises some concerns in the context of 80 
sports drug testing: its sampling is more invasive compared to urine, the collected volume is 81 
significantly lower and more accurate conditions for transportation and storage are needed.  82 
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In this work, a UHPLC-HRMS method was developed for the quantification of 11 endogenous 83 
steroid hormones in serum, including major androgens, progestogens and corticoids. The 84 
performance of the full scan (FS) and targeted selected ion monitoring (t-SIM) acquisition 85 
modes was evaluated and compared to that of UHPLC-MS/MS obtained in a previous work using 86 
samples from a testosterone clinical study [22]. Furthermore, in addition to quantitative 87 
performance, the ability to describe the exogenous testosterone administration by the three 88 
acquisition methods was also evaluated by means of an ANOVA-based multivariate statistical 89 
analysis.  90 
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2 Materials and methods 91 
2.1 Study samples  92 
Serum samples used for the method comparison were obtained from a T administration clinical 93 
trial (Swissmedic protocol n° 155/11) with 19 healthy male volunteers, who were administered 94 
twice with a T transdermal patch (Testopatch® 2.4 mg/24 h, Pierre Fabre Pharma GMBH, 95 
Freiburg, Germany) followed by T undecanoate capsules (Andriol Testocaps®, Essex Chemie AG, 96 
Luzern, Switzerland). The detailed description of the study is presented elsewhere [7]. 97 
2.2 Chemicals and reagents 98 
Available standards of endogenous steroids were purchased from Lipomed (Arlesheim, 99 
Switzerland), Cerilliant (Round Rock, TX, USA), Steraloids (Newport, RI, USA) and Sigma-Aldrich 100 
(Buchs, Switzerland), while all labeled internal standards (IS) were provided by the Australian 101 
Government National Measurement Institute (Pymble, Australia). Methanol (MeOH) was 102 
purchased from Macron Fine Chemicals (Deventer, Netherlands), and acetonitrile (ACN) ULC/MS 103 
(> 99%) and formic acid (FA) ULC/MS (99%) were supplied by Biosolve BV (Valkenswaard, 104 
Netherlands). Charcoal-dextran stripped human serum was obtained from Dunn Labortechnik 105 
GmbH (Asbach, Germany). Deionized water was obtained by a Milli-Q®-grade system (Millipore, 106 
USA) and was used for the preparation of all buffers and solutions. 107 
Analytes and IS mixture solutions were prepared in MeOH at appropriate concentrations and 108 
used for the preparation of calibration samples in depleted serum. Linear calibration curves 109 
were created for each analyte (weighting 1/x) to measure steroid concentration, and calibration 110 
samples were used for the extraction of lower limits of quantification (LLOQ) and accuracy 111 
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values of the method. Details concerning the composition and concentration of the calibration 112 
samples and IS mixtures are given in Supplementary Material Tables S1 and S2. 113 
2.3 Sample preparation and UHPLC conditions 114 
All the details concerning the extraction protocol and chromatographic conditions have been 115 
described in [22]. Briefly, a supported liquid extraction SLE+ 400 µL (Biotage, Uppsala, Sweden) 116 
in a 96 well-plate format was used to extract steroid hormones. Each serum sample (200 µL) 117 
was spiked with 20 µL of the IS mixture, diluted with 200 µL of water and then agitated for few 118 
minutes. Then, 400 µL of sample were loaded on each well and positive pressure of 3 psi was 119 
applied for 30 seconds to facilitate sample adsorption; after 5 minutes, the elution was carried 120 
out by adding 700 µL of DCM to each well and applying a pressure of 3 psi for 1 minute. After 121 
evaporation, 10 µL of reconstituted extracts were injected on a UPLC chromatographic system 122 
(Waters, Milford, MA, USA) equipped with an Ethylene Bridged Hybrid (BEH) C18 column (100 x 123 
2.1 mm, 1.7 µm; Waters) set at 30°C and a pre-column. The mobile phases consisted of (A) 0.1% 124 
formic acid in water and (B) 0.1% formic acid in ACN, and the flow rate was set at 400 µL/min. 125 
The gradient started linearly from 2% to 25% B over 0.5 min, followed by an increase to 58% B 126 
over 5.5 min and by a further increase to 98% B over 2 min; the column was then re-127 






2.4 MS conditions 132 
2.4.1 MS/MS analysis 133 
The UPLC system was coupled to a Xevo-TQ S triple quadrupole MS/MS system from Waters 134 
working in ESI positive and selected reaction monitoring (SRM) mode. The detailed instrumental 135 
UHPLC-MS/MS conditions (SRM transitions, ESI conditions, cone voltages and collision energies) 136 
are described in a previous article [22]. 137 
2.4.2 HRMS analysis 138 
HRMS analyses were performed by coupling the UPLC system to a Q Exactive Plus mass 139 
spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). Mass calibration (<3 ppm) was 140 
performed once a week using the Pierce® LTQ Velos ESI Positive Ion Calibration standard 141 
mixture (Thermo Fisher Scientific) containing n-butylamine, caffeine, MRFA (peptide of Met-Arg-142 
Phe-Ala acetate salt) and Ultramark 1621. Detection of the targeted steroids was performed in 143 
positive ESI in both FS and t-SIM acquisition modes. The heated ESI source (HESI II) was used 144 
with a probe heater temperature of 425°C, and the sheath gas and auxiliary gas pressures were 145 
set to 50 and 15 arbitrary units, respectively. The sweep gas flow was set to 3 arbitrary units. 146 
The ion spray voltage was set to 4.5 kV, the capillary temperature to 250°C and the S-Lens RF 147 
level was 55%. FS mass spectra were acquired using a mass resolution of 70,000 (full width at 148 
half maximum, FWHM) at m/z 200, with a maximum IT fill time of 250 ms and the automatic 149 
gain control (AGC target) set to 1e6. The acquired mass range was from m/z 200 to 600. The t-150 
SIM acquisition mode was also performed using a mass resolution of 70,000 FWHM, with a 151 
maximum IT fill time of 250 ms and the AGC target set to 5e4. An isolation window of 0.4 m/z 152 
was set, and the maximum number of precursor ions to be multiplexed in a scan event (MSX 153 
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count) was from 2 to 8, depending on the proximity of the analytes in terms of retention times. 154 
All extracted chromatograms were obtained using an extraction window of 10 ppm. 155 
2.5 Comparison of quantitative performance  156 
The comparison between HRMS and MS/MS methods was performed employing two different 157 
approaches. First, the correlation of the steroid concentrations obtained with the two methods 158 
was evaluated using the Passing-Bablok regression together with Bland-Altman plots; the latter 159 
helped evaluate the bias, as they correspond to regression residual plots. Then, a multivariate 160 
data analysis, involving analysis of variance multiblock orthogonal partial least squares 161 
(AMOPLS), was applied to simultaneously investigate signal variations related to the different 162 
experimental factors, i.e., inter-individual, temporal and method-related sources of variability, 163 
and their potential interactions. Indeed, AMOPLS allows the reliability of experimental effects to 164 
be objectively evaluated using a specific effect-to-residual ratio. The aim of this second 165 
approach was not to provide an absolute evaluation of the variations caused by the different 166 
quantification methods but to fairly compare and establish the relative impact of each source of 167 
variability in the obtained dataset. Random permutations of the design matrix simulate data 168 
under the null hypothesis (i.e., no effect), and the values obtained can be compared to the 169 
experimental value. AMOPLS models were computed under the MATLAB 8 environment (The 170 
MathWorks, Natick, MA, USA) and compared to a series of 103 random permutations. 171 
  172 
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3. Results and discussion 173 
3.1 Optimization of HRMS conditions  174 
The chromatographic conditions were already optimized in a previous study [22] allowing a 175 
satisfactory separation of the analytes, especially in the case of 11-deoxycortisol and 176 
corticosterone, which had the same exact mass and close retention times.In this work, the 177 
method development was mainly focused on the optimization of HRMS conditions. Details of 178 
the detection parameters are presented in Table 1 for the target analytes and in Supplementary 179 
Material Table S3 for the labeled internal standards (IS). First, all the ESI source parameters 180 
were tuned to obtain the best sensitivity. As DHT proved to have the lowest ionization efficiency 181 
among the 11 analytes, it was chosen as the target compound, and direct infusion of a DHT 182 
standard in MeOH at 1 μg/mL was performed. In addition, this compound had already been 183 
highlighted as a promising biomarker of testosterone administration in serum [22].  184 
Then, the first investigated acquisition mode was the FS. The scan range was set from 200 to 185 
600 m/z, allowing the detection of all steroid hormone ions and their potential adducts; the 186 
resolution, AGC target and Maximum IT were optimized with the aim of obtaining a sufficient 187 
number of acquisition data points over each chromatographic peak. For that, a target range of 188 
10-15 data points was set for acquisition. An example chromatogram for 17αOH-progesterone 189 
at 1 ng/mL obtained in FS mode is shown in Figure 1A, where 16 data points over the peak were 190 
obtained with a resolution of 70,000 FWHM. Because some of the target steroids, such as 191 
epitestosterone, progesterone and DHT, are known to be at a very low concentration in serum, 192 
a t-SIM experiment was also evaluated with the aim of enhancing sensitivity. For this purpose, 193 
preliminary experiments using a single t-SIM event were carried out during the whole 194 
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chromatographic run. For this experiment, an inclusion list containing m/z values of all target 195 
hormones and relative internal standards ions was created, and the acquisition was performed 196 
setting the multiplexing (MSX) count to 1. As shown in Figure 1B, this strategy was not 197 
satisfactory to obtain a sufficient number of data points across the peak, also compromising 198 
sensitivity. Indeed, in the retention time window where 17αOH-progesterone eluted (from 5 to 199 
5.5 min), three other analytes, as well as their respective IS, were detected, reaching a total of 8 200 
compounds (see Table 1). This meant that in this specific time window, after each FS event, only 201 
one of the 8 present ions was allowed to enter the C-Trap and be analyzed, resulting in a limited 202 
number of acquisitions in t-SIM mode for all the compounds in this time period (7 points under 203 
the peak in the case of Figure 1B). To resolve this issue, a different t-SIM experiment was then 204 
performed making use of the MSX function, depending on the number of compounds co-eluting 205 
in the same time window. MSX values from 2 (only the target analyte and its internal standard) 206 
up to 8 (four analytes and their relative IS) were selected (see Table 1). After each FS event, the 207 
ions of all co-eluting multiplexed compounds were accumulated in the C-trap and subsequently 208 
analyzed. This second strategy proved to be efficient, allowing a number of acquisition points 209 
similar or equal to the FS acquisition for all target steroids. As observed in Figure 1C, by applying 210 
an MSX count of 8, it was possible to obtain a very satisfactory peak shape with approximately 211 
16 data points for 17αOH-progesterone with the multiplexed t-SIM acquisition mode.  212 
Concerning sensitivity, the t-SIM acquisition provided an increased signal to noise (S/N) ratio, in 213 
particular for DHT, one of the two blood markers of T administration previously highlighted: a 214 
significant increase in the S/N from 9 to 32 RMS (root mean square) was observed passing from 215 
FS to multiplexed t-SIM, despite no remarkable augmentation of peak area. For analytes with a 216 
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low concentration and/or poor ionization in the ESI source, the t-SIM acquisition mode could, 217 
therefore, represent the optimal solution for quantification purposes, assuming the utilization 218 
of MSX count. 219 
3.2 Comparison of quantitative performance 220 
Once the HRMS conditions were optimized, 491 serum samples collected during a testosterone 221 
administration clinical study were prepared and analyzed using both of the developed UHPLC-222 
HRMS and UHPLC-MS/MS methods. For comparison purposes, concentrations of 11 target 223 
steroids were measured by means of the three different acquisition modes: FS, multiplexed t-224 
SIM and SRM. 225 
Epitestosterone, progesterone and deoxycorticosterone were present in serum at very low 226 
concentrations (below 100 pg/mL), and it was not possible to detect them with the HRMS 227 
platform; therefore, they were discarded for the following comparison.  228 
3.2.1 Assay correlation 229 
For each of the 8 sufficiently concentrated compounds, Passing-Bablok regressions [23] and 230 
Bland-Altman plots [24, 25] were assessed, using MS/MS values as a reference method. The 231 
plots obtained for T and DHT are presented in Figures 2 and 3, respectively, and discussed 232 
herein in more detail, while the graphs for all remaining compounds are shown in 233 
Supplementary Material Figures S1-S6. 234 
For the Passing-Bablok regression, the parameters that were evaluated were the slope, the 235 
intercept, and the determination coefficient (R2). For the Bland-Altman plots, the percentage of 236 
samples with a difference of measured concentrations between ±20% (arbitrary acceptability 237 
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range [26]) was evaluated. In both cases, the T concentration measured with the HRMS method 238 
correlated well with MS/MS. In the t-SIM vs SRM plot (Figure 2A), the samples were less spread 239 
than in the FS vs SRM plot (Figure 2B), resulting in a better determination coefficient; this 240 
dispersion of the samples is more pronounced in the high concentration region. Moreover, a 241 
slope value close to one was found for both regressions, while the obtained intercept had a 242 
negative value in both cases, suggesting a minor underestimation of T concentration with both 243 
HRMS methods. According to the Bland-Altman plots, for a high percentage of samples (99.6% 244 
and 93.9%, respectively), measured T concentration differences were within the acceptability 245 
limits arbitrarily defined for both t-SIM (Figure 2C) and FS (Figure 2D); mean biases of -3.615% 246 
and 0.298% were observed comparing MS/MS measurements with the t-SIM and FS results, 247 
respectively.  248 
In Figure 3, the plots of the DHT measurement comparison are presented. Looking at Passing-249 
Bablok regressions, similar results to T were obtained, demonstrating a good correlation 250 
between different quantification results, considering slope values close to one and satisfactory 251 
R2 for both HRMS methods (0.9328 t-SIM, 0.9013 FS). On the other hand, there was a lower 252 
percentage of samples within the acceptability limits (82.7% t-SIM, 73.5% FS) and a higher mean 253 
bias from SRM quantification (6.48% t-SIM, 6.89% FS) evaluating Bland-Altman plots. For 254 
concentrated analytes such as T, HRMS measurements appear to be a valuable alternative to 255 
classical MS/MS experiments. However, the higher dispersion of samples in Bland-Altman plots 256 
in the low concentration region suggests that HRMS measurements are slightly less sensitive 257 
than MS/MS. This could be an issue for the less concentrated analytes such as DHT, especially 258 
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when FS acquisition is considered. In this context, the t-SIM acquisition mode could reduce the 259 
gap with MS/MS quantification, thanks to a significant increase in sensitivity.  260 
To further investigate this aspect, calibration curves were constructed and LLOQ values were 261 
estimated for all steroid hormones with both the FS and t-SIM developed methods. First, several 262 
regression models were tested to select the most suitable and simple response function. 263 
Because the hypothesis of variance homogeneity was rejected, the simplest regression model 264 
without data transformation, based on the least squares method, could not be retained. 265 
Therefore, the best weighting factor was chosen taking into account the relationship between 266 
the logarithm of the natural variance and the concentration as described elsewhere [27]. For 267 
each analyte, the specially selected weighting factor was the inverse of the concentration raised 268 
to the λth power (1/x λ), λ being the slope of the line fitted to the data on the logarithm scale. 269 
Hence, the mean selected weighting factor was round off the inferior unit and determined to be 270 
1/x. Then, the lowest concentration at which the back-calculated concentration of the 271 
calibration curves exhibited a precision that did not exceed 20% of the CV and accuracy within 272 
20% of the nominal concentration was evaluated. This approach, in accordance with official 273 
guidelines such as the FDA [28], permitted obtaining the LLOQ values shown in Table 2 together 274 
with those of the reference MS/MS method. The accuracy and repeatability details for all target 275 






3.2.2 Multivariate data analysis 280 
In addition to the classical comparison of the analytical methods for each of the measured 281 
target compounds discussed above, a more global approach has also been applied to evaluate 282 
the quality of the measurements obtained using HRMS. A multivariate data analysis method 283 
based on ANOVA and PLS, namely AMOPLS, which was recently proposed for the analysis of 284 
omics data generated from designed experiments [29], was used for proper data analysis 285 
accounting for both the highly multivariate structure of the data and the study design. Indeed, 286 
multifactorial experiments, such as the analysis of clinical study samples, generate data 287 
simultaneously altered by several sources of variation. The systematic strategy proposed herein 288 
is particularly well suited to gather information on the potential effects of experimental factors 289 
and their interactions, and it was demonstrated to be a relevant tool to disentangle the 290 
influences of specific factors or interactions in multifactorial experiments, with a simplified 291 
interpretation of signal variations based on specific sets of scores and loadings related to each 292 
effect. 293 
Two separate AMOPLS models were therefore computed based on the combination of 294 
quantitative data from the 8 steroid hormones measured by all three analytical methods in 295 
blood control samples and samples collected after transdermal and oral T administrations. Unit 296 
variance scaling was applied to analyte concentration variations, avoiding their impact in 297 
intensity range. The main effects of the three experimental factors taken into account for this 298 
study, namely inter-individual variability (Volunteer factor, 19 levels), longitudinal signal 299 
variations (Time factor, 16 levels) and differences due to the quantification strategy (Method 300 
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factor, 3 levels), as well as their first-order interactions (Volunteer*Time, Volunteer*Method and 301 
Time*Method) were included in the models.  302 
Concerning the transdermal administration, as a first investigation of signal variations, the 303 
relative contribution related to each effect and interactions (expressed as sum of squares) was 304 
computed to obtain the following values: Volunteer 29.7%, Time 38.6%, Method 0.8%, 305 
Volunteer*Time 28.9%, Volunteer*Method 0.8%, Time*Method 0.2% and Residuals 1.0%. These 306 
results, shown in Figure 4A, clearly highlight the strong influence of the inter-individual 307 
variability in the measured steroids levels, together with marked alterations during the 308 
temporal follow-up. Interestingly, the cumulative proportion of signal variations due to the 309 
different quantification strategies (SRM and HRMS in both FS and t-SIM modes) was very low 310 
(main effect+interactions <2%).  311 
Random permutations of the experimental design were then carried out to evaluate the 312 
statistical significance of the results. The comparison with random designs highlighted the main 313 
effect due to the Time factor as the only significant structured source of variation in the dataset 314 
(p<0.01). Notably, despite an important proportion of total variability related to the Volunteer 315 
factor, all the other ANOVA terms were declared non-significant (p>0.05). This may be because 316 
inter-individual variations are related to biological noise. While no major structure emerges 317 
from these uncoordinated differences, these results also confirmed that the very low 318 
contribution related to the Method factor was statistically negligible. Total inter-individual 319 
variability is obtained by summing the main effect of the Volunteer factor (differences between 320 
individuals on average over all time points) and the interaction effect between Volunteer and 321 
Time (differences between the evolutions over time). 322 
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Predictive components related to the Time factor were then further investigated to highlight 323 
trends in the sample distributions (Supplementary Material Figure S7A). The most important 324 
temporal pattern was associated with a circadian modulation of steroid levels, clearly visible on 325 
the first latent variable associated with the Time factor (47.9%). This pattern confirms the 326 
results previously obtained by MS/MS and was mainly associated with androstenedione, DHEA, 327 
corticosterone, cortisol, and 11-deoxycortisol. Additionally, the effect of T transdermal intake 328 
was observable on the second component associated with the Time factor (30.3%) (Figure 4B), 329 
characterized by a marked increase until 12 h after administration and a slow decrease until 48 330 
h. The major biomarkers associated with this trend were T and DHT.  331 
In the same fashion as transdermal administration, differences due to inter-individual and 332 
temporal variability were responsible for the largest variations of the dataset of the oral 333 
testosterone undecanoate (TU) intake, as illustrated by the relative sum of squares related to 334 
each effect in Figure 5A: Volunteer 26.5%, Time 31.3%, Method 0.6%, Volunteer*Time 35.7%, 335 
Volunteer*Method 0.9%, Time*Method 0.4% and Residuals 4.5%. According to random 336 
permutations, the only significant effect was related to the Time factor (p<0.01), while all other 337 
effects were deemed non-significant (p>0.05). Investigating the Time factor (Supplementary 338 
Material Figure S7B), similarly to the transdermal administration, a circadian rhythm was found 339 
as the major source of variability (53.5% of the Time factor), with marked modulations of DHEA, 340 
corticosterone, cortisol, and 11-deoxycortisol. Moreover, the effect of oral T administration was 341 
observed on the second component related to the Time factor (18.6%, Figure 5B). Altered levels 342 
of T, DHT and androstenedione were associated with an increase of the temporal trajectory 343 
after 2 and 4 h and a return to the basal situation. 344 
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Taking all this information, these results are perfectly in line with our previous study based on 345 
multiway modeling [22], highlighting the marked impact of inter-individual differences and 346 
intra-day variations. The decomposition of the different sources of variability can constitute an 347 
objective basis for the selection of biomarkers less affected by these factors. The data mining 348 
strategy was able to efficiently decompose the different sources of variation and investigate the 349 
impact of T administration in the presence of confounders or other experimental factors, a 350 
situation commonly found in the anti-doping routine analysis. 351 
  352 
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4. Conclusions 353 
Measurement of endogenous steroid hormones in serum has been recently proven to be an 354 
interesting complementary strategy to the current urinary steroid profile for the detection of 355 
steroid-related doping abuse. In this research study, the potential of HRMS analysis in this 356 
context was evaluated by developing an UHPLC-HRMS method for the quantification of some of 357 
the most important endogenous steroids in serum related to testosterone metabolism. Its 358 
analytical performance was then compared to that of an already validated UHPLC-MS/MS 359 
method by analyzing serum samples collected during a testosterone clinical study. The results 360 
showed that for the 8 analytes that were detected with all three employed acquisition methods, 361 
concentration values measured by HRMS strongly correlated with the ones measured by 362 
MS/MS. Only in the case of low concentration steroids, such as DHT and 11-deoxycortisol, was a 363 
higher dispersion of samples in Bland-Altman plots observed in the low concentration region. 364 
This was probably due to a sensitivity gap between HRMS and MS/MS, which could be partially 365 
counterbalanced by the multiplexed t-SIM approach. The evaluation of HRMS performance was 366 
also investigated with a complementary approach based on ANOVA decomposition and 367 
multivariate analysis. Among the factors of variability, the AMOPLS showed that the influence of 368 
quantification Method was negligible (<2% of the total variance) in both transdermal and oral 369 
administration datasets, hence giving a biological description of testosterone intake fully in 370 
accordance with already published research based on UHPLC-MS/MS quantification.  371 
This study noted the suitability of UHPLC-HRMS systems for the quantification of endogenous 372 
steroid hormones in serum (Quan), confirming this matrix as a promising aid to improve steroid 373 
abuse detection in the anti-doping field. In addition, the possibility to acquire data in HRMS 374 
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FullScan mode opens the way to untargeted studies (Qual) for new metabolites identification. 375 
Qual-Quan acquisition will be of great usefulness, in particular in the anti-doping context, 376 
where most of WADA accredited laboratories are increasing their investments on HRMS 377 
instruments.  378 
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Table 1 - Description of target analytes and detection parameters 485 
Analyte Elemental Composition 








(monoisotopic)           
[m/z] 
Mass Error                      
[ppm] 




Testosterone C19H28O2 4.61 289.12579 289.21621 0.93 2 4.1 - 4.7 
Epitestosterone C19H28O2 5.31 289.21582 289.21621 1.35 8 4.6 - 5.5 
Androstenedione C19H26O2 5.13 287.20026 287.20056 0.84 8 4.6 - 5.5 
Progesterone C21H30O2 6.85 315.23157 315.23186 0.54 2 6.2 - 7.2 
17α-Hydroxyprogesterone C21H30O3 5.26 331.22641 331.22677 1.27 8 4.6 - 5.5 
DHEA C19H28O2 5.10  271.20535°   271.20564° 0.96 8 4.6 - 5.5 
DHT C19H30O2 5.60 291.23175 291.23186 1.10 2 5.3 - 5.7 
Corticosterone C21H30O4 3.63 347.22122 347.22169 0.72 3 3.1 - 4.1 
Cortisol C21H30O5 2.77 363.21619 363.21660 1.57 2 2.3 - 3.0 
Deoxycorticosterone C21H30O3 4.86 331.22638 331.22677 1.09 2 4.5 - 5.0 
11-Deoxycortisol C21H30O4 3.77 347.22124 347.22169 1.01 3 3.1 - 4.1 
* Also taking into account the deuterated internal standard for each target analyte        
° [M-H2O]+               
27 
 
Table 2 – Estimated lower limit of quantification (LLOQ) for target analytes with FS and t-SIM acquisition 486 
modes in comparison with the MS/MS method 487 
Compound 
LLOQ [pg/mL] 
FS t-SIM MS/MS[22] 
Testosterone 100 50 20 
Epitestosterone 100 50 20 
Androstenedione 100 50 50 
17α-Hydroxyprogesterone 500 250 100 
Progesterone 100 50 15 
DHEA 500 500 500 
DHT 500 250 50 
Corticosterone 100 100 100 
Cortisol 1000 1000 1000 
Deoxycorticosterone 500 250 25 




  491 
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Figures captions 492 
Figure 1 Chromatograms of 17α-hydroxyprogesterone obtained with three different HRMS 493 
acquisition modes: (A) Full scan, (B) t-SIM without multiplexing and (C) t-SIM with MSX count of 494 
8  495 
Figure 2 Passing-Bablok regressions and Bland-Altman plots for the comparison of testosterone 496 
quantification results. (A, B) t-SIM vs SRM and (C, D) FS vs SRM 497 
Figure 3 Passing-Bablok regressions and Bland-Altman plots for the comparison of DHT 498 
quantification results. (A, B) t-SIM vs SRM and (C, D) FS vs SRM  499 
Figure 4 AMOPLS modeling for transdermal administration data (30.3% of explained variance): 500 
(A) relative contributions of volunteer, time and method effects and their interactions; (B) score 501 
and loadings plots of predictive component related to the time factor. C: control, P: patch. 502 
Figure 5 AMOPLS modeling for oral administration data (18.6% of explained variance): (A) 503 
relative contributions of volunteer, time and method effects and their interactions; (B) score and 504 
loadings plots of predictive component related to the time factor. C: control, O: oral. 505 
 506 




































5.19 NL: 2.09E5 
m/z=  331.22346- 331.23008 
F: FTMS + p ESI SIM ms 
[331.03-331.43]   
NL: 5.66E5 
m/z=  331.22346- 331.23008 
F: FTMS + p ESI SIM msx ms 
[331.03-331.43]   
5.26 
NL: 5.60E5 
m/z=  331.22346- 331.23008 
F: FTMS + p ESI Full ms 




















































y = 1,030x - 407,146 


















































y = 1,096x - 571,808 
















































y = 1,032x + 14,787 














































y = 1,085x + 0,925 


















Scores – tp2 Loadings – tp2 B 
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Scores – tp2 Loadings – tp2 B 
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Time x Method 
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Residuals 
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     26.5% 
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    0.6% 
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Volunteer x Method 
              0.9% 
Volunteer x Time 
            35.7% 
Table S1 Internal Standard Mix composition (final conc. in serum) 
Compound Concentration (ng/mL) Compound 
Concentration 
(ng/mL) 
   Testosterone-d3  0,2    DHT-d3  2 
   Epitestosterone-d3  0,5    Corticosterone-d8  5 
   Androstenedione-d7  5    Cortisol-d4  2,5 
   Progesterone-d9  2    Deoxyorticosterone-d8 2 
   17α-Hydroxyprogesterone-d8 10    11-Deoxycortisol-d2  1 
   DHEA-d5  4 
Table S2 Calibration samples composition (final conc. in serum) 
Compound 
Concentration (pg/mL) 
Cal1 Cal2 Cal3 Cal4 Cal5 Cal6 Cal7 Cal8 
Testosterone 20 50 100 500 1000 5000 10000 25000 
Epitestosterone 20 50 100 500 1000 2500 10000 
Androstenedione 50 100 500 1000 2500 5000 10000 25000 
Progesterone 15 25 50 100 500 2500 10000 25000 
17α-Hydroxyprogesterone 100 250 500 1000 2500 500 10000 25000 
DHEA 500 2500 5000 10000 25000 
DHT 50 250 500 750 1000 2500 5000 10000 
Corticosterone 100 500 1000 5000 25000 50000 100000 
Cortisol 1000 2500 10000 25000 100000 200000 300000 400000 
Deoxycorticosterone 25 250 500 1000 2500 10000 
11-Deoxycortisol 25 250 500 1000 2500 5000 
Table S3 Description of labeled internal standards and detection parameters 
Analyte Elemental Composition 
Retention Time     
[min] 
Observed Ion Mass 
(monoisotopic)     
[m/z] 
Theoretical Ion Mass 
(monoisotopic)          
[m/z] 
Mass Error     
[ppm] 




Testosterone-d3 C19H25D3O2 4.58 292.23484 292.23431 1.81 2 4.1 - 4.7 
Epitestosterone-d3 C19H25D3O2 5.28 292.23484 292.23431 1.81 8 4.6 - 5.5 
Androstenedione-d7 C19H19D7O2 5.10 294.24429 294.24384 1.53 8 4.6 - 5.5 
Progesterone-d9 C21H21D9O2 6.81 324.28835 324.28784 1.57 2 6.2 - 7.2 
17α-Hydroxyprogesterone-d8 C21H22D8O3 5.24 339.27679 339.27628 1.50 8 4.6 - 5.5 
DHEA-d5 C19H23D5O2 5.07 276.23703 276.23706 -0.11 8 4.6 - 5.5 
DHT-d3 C19H27D3O2 5.58 294.25069 294.25027 1.43 2 5.3 - 5.7 
Corticosterone-d8 C21H22D8O4 3.60 355.27190 355.27155 0.99 3 3.1 - 4.1 
Cortisol-d4 C21H26D4O5 2.77 367.24171 367.24142 0.79 2 2.3 - 3.0 
Deoxycorticosterone-d8 C21H22D8O3 4.82 339.27699 339.27634 1.92 2 4.5 - 5.0 
11-Deoxycortisol-d2 C21H28D2O4 3.75 349.23424 349.23384 1.15 3 3.1 - 4.1 
° [M-H2O]+ 
 Figure S1 – Passing-Bablok regressions and Bland-Altman plots for androstenedione 
 
 Figure S2 - Passing-Bablok regressions and Bland-Altman plots for 17α-hydroxyprogesterone 














Figure S4 - Passing-Bablok regressions and Bland-Altman plots for corticosterone 
 Figure S5 - Passing-Bablok regressions and Bland-Altman plots for cortisol 












Table S4 –Trueness, repeatability and intermediate precision calculated for all analytes at each 
concentration level with t-SIM acquisition mode. Highlighted in grey LLOQ values, defined as 
the lowest concentration at which measured accuracy and precision are <20%. 
          
Analyte Concentration                     (pg/mL) 
Trueness     
(%)* 
Precision 
Repeatability      
(%, n=2) IP  (%, n=12)* 
Testosterone 20 127.0 5.5 12.9 
  50 94.5 11.1 12.0 
  100 94.6 4.3 5.6 
  500 91.4 9.3 9.3 
  1000 92.8 7.4 7.7 
  5000 105.2 13.1 13.1 
  10000 91.8 7.7 7.7 
  25000 104.0 7.9 7.9 
          
Epitestosterone 20 -  -  -  
  50 116.4 14.0 14.0 
  100 111.6 11.1 11.1 
  500 89.4 5.0 5.1 
  1000 84.6 7.0 7.1 
  2500 94.9 6.4 6.8 
  10000 157.8 14.0 14.0 
          
Androstenedione 50 100.3 13.3 14.0 
  100 95.1 7.6 12.4 
  500 100.9 8.6 8.6 
  1000 98.0 9.5 9.5 
  2500 101.1 5.0 5.0 
  5000 103.7 5.2 8.3 
  10000 95.6 9.0 9.0 
  25000 101.8 6.9 6.9 
          
Progesterone 15 98.5 48.0 48.0 
  25 93.5 23.6 23.6 
  50 93.0 9.2 10.0 
  100 99.0 16.6 16.6 
  500 103.5 19.1 19.1 
  2500 102.2 12.5 13.7 
  10000 101.0 13.0 13.0 














17α-hydroxyprogesterone 100 102.0 23.8 23.8 
  250 90.1 10.3 10.3 
  500 95.3 12.1 12.1 
  1000 102.5 9.0 10.2 
  2500 97.0 7.0 10.3 
  5000 95.4 4.5 7.4 
  10000 97.0 9.9 11.1 
  25000 101.7 6.9 6.9 
          
DHEA 500 117.4 6.6 6.6 
  2500 87.5 6.9 6.9 
  5000 95.8 8.8 9.0 
  10000 89.1 7.1 7.1 
  25000 106.2 5.2 5.2 
          
DHT 50 101.3 23.4 23.4 
  250 85.1 4.8 5.0 
  500 108.2 6.5 8.2 
  750 105.6 6.6 7.4 
  1000 108.2 3.0 6.2 
  2500 98.0 9.1 9.1 
  5000 92.4 6.3 6.3 
  10000 106.0 4.5 4.9 
          
Corticosterone 100 104.1 16.7 17.3 
  1000 100.0 10.9 11.3 
  5000 96.0 11.0 11.0 
  25000 100.2 11.6 11.6 
  50000 105.2 7.5 9.4 
  100000 95.8 8.1 10.8 
          
Cortisol 1000 108.8 8.7 9.9 
  2500 89.2 6.4 6.4 
  10000 98.7 7.8 9.4 
  25000 101.4 5.9 9.6 
  100000 97.2 7.5 9.2 
  200000 99.0 11.1 11.1 
  300000 94.1 9.6 9.6 









Deoxycorticosterone 25  - -  -  
  250 101.1 13.0 17.3 
  500 118.7 16.5 19.3 
  1000 119.4 8.3 16.4 
  2500 119.0 2.8 10.4 
  10000 87.5 3.9 6.0 
          
11-deoxycortisol 25 153.9 36.1 36.1 
  250 86.8 7.2 9.1 
  500 86.6 6.8 12.4 
  1000 83.6 8.5 8.7 
  2500 90.4 16.2 16.2 
  5000 87.7 7.8 11.7 
*IP: Intermediate Precision  
- : analyte not detected 
















Table S5 –Trueness, repeatability and intermediate precision calculated for all analytes at each 
concentration level with FS acquisition mode. Highlighted in grey LLOQ values, defined as the 
lowest concentration at which measured accuracy and precision are <20%. 
Analyte Concentration                     (pg/mL) 
Trueness     
(%)* 
Precision 
Repeatability      
(%, n=2) IP (%, n=12)* 
Testosterone 20 146.2 19.2 35.8 
  50 110.4 9.6 29.9 
  100 92.1 16.3 16.3 
  500 86.2 13.7 14.6 
  1000 87.8 11.4 11.4 
  5000 109.2 12.4 12.4 
  10000 91.9 14.3 14.3 
  25000 106.3 4.6 6.0 
          
Epitestosterone 20 -  -  -  
  50 -  -  -  
  100 115.6 19.1 19.1 
  500 97.2 18.6 18.6 
  1000 90.2 15.8 15.8 
  2500 99.0 14.5 14.5 
  10000 101.0 8.1 8.1 
          
Androstenedione 50 115.8 34.2 39.2 
  100 100.5 17.8 17.8 
  500 94.2 15.9 15.9 
  1000 100.5 3.2 5.6 
  2500 100.1 4.9 6.3 
  5000 101.5 4.2 5.5 
  10000 96.5 7.6 7.6 
  25000 101.2 2.3 3.2 
          
Progesterone 15 121.6 59.7 59.7 
  25 101.7 31.1 43.3 
  50 106.5 34.4 34.4 
  100 93.7 9.2 9.7 
  500 94.8 4.1 7.5 
  2500 95.9 5.0 5.0 
  10000 98.2 6.5 6.5 














    
 
 
17α-hydroxyprogesterone 100 -  - - 
  250 89.4 12.1 27.0 
  500 86.9 16.5 16.7 
  1000 109.3 7.6 11.7 
  2500 94.5 8.8 8.8 
  5000 98.2 2.0 6.3 
  10000 95.5 8.6 8.6 
  25000 101.3 8.7 8.7 
          
DHEA 500 117.9 2.6 2.7 
  2500 87.0 8.8 8.8 
  5000 93.8 3.6 6.7 
  10000 87.3 3.5 4.5 
  25000 107.3% 4.4 4.4 
          
DHT 50 109.6 21.2 21.2 
  250 79.7 4.4 5.0 
  500 105.1 10.3 10.3 
  750 101.9 7.5 8.6 
  1000 110.4 8.3 9.2 
  2500 97.1 6.7 7.1 
  5000 92.3 6.2 6.2 
  10000 105.2 5.2 5.2 
          
Corticosterone 100 101.9 13.9 15.8 
  1000 100.6 15.4 15.4 
  5000 94.2 9.2 10.6 
  25000 100.1 12.6 12.6 
  50000 105.1 8.3 9.1 
  100000 96.9 6.8 10.4 
          
Cortisol 1000 112.9 5.0 7.1 
  2500 88.2 3.4 3.4 
  10000 98.1 5.4 5.8 
  25000 101.0 2.4 5.6 
  100000 99.2 3.4 5.7 
  200000 98.1 5.4 5.6 
  300000 93.5 7.8 7.8 






        
 
 
Deoxycorticosterone 25  -  -  - 
  250 83.6 9.5 22.1 
  500 111.2 15.7 15.7 
  1000 119.1 17.7 17.9 
  2500 119.8 18.7 18.7 
  10000 92.9 5.6 5.6 
          
11-deoxycortisol 25 162.5 18.5 26.3 
  250 83.7 4.9 10.1 
  500 83.3 6.4 9.7 
  1000 81.6 8.5 9.8 
  2500 88.6 20.0 20.0 
  5000 89.2 11.0 11.0 
*IP: Intermediate Precision  
- : analyte not detected 


















 Figure S7 - Score and loadings plots of time modes of tp 1 obtained from AMOPLS modeling for 
(A) transdermal administration data (47.9% of explained variance) and (B) oral administration 
data (53.5% explained variance). C: control, P: patch, O: oral 
 
